Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.

Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I; SIR, SIDeMaST, and IG-IBD.

Autoimmun Rev. 2014 Jul;13(7):751-5. doi: 10.1016/j.autrev.2014.02.004. Epub 2014 Mar 19. Review.

PMID:
24657898
2.

[Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].

Schreiber S, Luger T, Mittendorf T, Mrowietz U, Müller-Ladner U, Schröder J, Stallmach A, Bokemeyer B.

Dtsch Med Wochenschr. 2014 Nov;139(47):2399-404. doi: 10.1055/s-0034-1387371. Epub 2014 Nov 12. German.

PMID:
25390629
3.

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.

Annese V, Vecchi M; Italian Group for the Study of IBD (IG-IBD).

Dig Liver Dis. 2014 Nov;46(11):963-8. doi: 10.1016/j.dld.2014.07.019. Epub 2014 Aug 17. Review.

PMID:
25139379
4.

The biosimilar road in inflammatory bowel disease: the right way?

Fiorino G, Danese S.

Best Pract Res Clin Gastroenterol. 2014 Jun;28(3):465-71. doi: 10.1016/j.bpg.2014.04.006. Epub 2014 May 4. Review.

PMID:
24913385
5.

Biosimilars in inflammatory bowel disease: ready for prime time?

Gomollón F.

Curr Opin Gastroenterol. 2015 Jul;31(4):290-5. doi: 10.1097/MOG.0000000000000184. Review.

PMID:
26039720
7.

Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease--Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases.

Azevedo VF, Meirelles Ede S, Kochen Jde A, Medeiros AC, Miszputen SJ, Teixeira FV, Damião AO, Kotze PG, Romiti R, Arnone M, Magalhães RF, Maia CP, de Carvalho AV.

Autoimmun Rev. 2015 Sep;14(9):769-73. doi: 10.1016/j.autrev.2015.04.014. Epub 2015 May 1. Review.

PMID:
25936608
8.

The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?

Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.

Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:27-34. doi: 10.1586/17474124.2015.1091307. Review.

PMID:
26395532
9.

Biosimilars in the therapy of inflammatory bowel diseases.

Hlavaty T, Letkovsky J.

Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7. doi: 10.1097/MEG.0000000000000098. Review.

PMID:
24722561
10.

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.

de Ridder L, Waterman M, Turner D, Bronsky J, Hauer AC, Dias JA, Strisciuglio C, Ruemmele FM, Levine A, Lionetti P; ESPGHAN Paediatric IBD Porto Group.

J Pediatr Gastroenterol Nutr. 2015 Oct;61(4):503-8. doi: 10.1097/MPG.0000000000000903.

PMID:
26154031
11.

Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.

Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.

Aliment Pharmacol Ther. 2015 Nov;42(10):1158-69. doi: 10.1111/apt.13402. Epub 2015 Sep 13. Review.

12.

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

Danese S, Gomollon F; Governing Board and Operational Board of ECCO.

J Crohns Colitis. 2013 Aug;7(7):586-9. doi: 10.1016/j.crohns.2013.03.011. Epub 2013 Apr 25.

13.

Clinical trial development for biosimilars.

Alten R, Cronstein BN.

Semin Arthritis Rheum. 2015 Jun;44(6 Suppl):S2-8. doi: 10.1016/j.semarthrit.2015.04.002. Review.

14.
15.

Inflammatory diseases: Integrating biosimilars into clinical practice.

Feldman SR.

Semin Arthritis Rheum. 2015 Jun;44(6 Suppl):S16-21. doi: 10.1016/j.semarthrit.2015.04.003. Epub 2015 Apr 9.

PMID:
26058549
16.

Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).

Vermeire S, Louis E, Dewit O, Franchimont D, Moreels T, Ferrante M, Rahier JF, Van Hootegem P, De Vos M, Mana F, Baert F; Belgian IBD Research & Development (BIRD).

Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):26-9. No abstract available.

PMID:
26118575
17.

Biosimilars in inflammatory bowel disease.

Gargallo CJ, Lué A, Gomollón F.

Minerva Med. 2017 Jun;108(3):239-254. doi: 10.23736/S0026-4806.17.05050-9. Epub 2017 Feb 7. Review.

PMID:
28176515
18.

Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.

Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J.

J Intern Med. 2016 Jan;279(1):41-59. doi: 10.1111/joim.12432. Epub 2015 Sep 25. Review.

PMID:
26403380
19.

Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.

Teixeira FV, Kotze PG, Damião AO, Miszputen SJ.

Arq Gastroenterol. 2015 Jan-Mar;52(1):76-80. doi: 10.1590/S0004-28032015000100016.

20.

Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.

Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL.

Clin Gastroenterol Hepatol. 2016 Dec;14(12):1685-1696. doi: 10.1016/j.cgh.2016.05.023. Epub 2016 May 21. Review.

Supplemental Content

Support Center